TY - JOUR
T1 - Thallium Labeled Citrate-Coated Prussian Blue Nanoparticles as Potential Imaging Agent
AU - Szigeti, Krisztián
AU - Hegedus, Nikolett
AU - Rácz, Kitti
AU - Horváth, Ildikó
AU - Veres, Dániel S.
AU - Szöllosi, Dávid
AU - Futó, Ildikó
AU - Módos, Károly
AU - Bozó, Tamás
AU - Karlinger, Kinga
AU - Kovács, Noémi
AU - Varga, Zoltán
AU - Babos, Magor
AU - Budán, Ferenc
AU - Padmanabhan, Parasuraman
AU - Gulyás, Balázs
AU - Máthé, Domokos
N1 - Publisher Copyright:
© 2018 Krisztián Szigeti et al.
PY - 2018/4/26
Y1 - 2018/4/26
N2 - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.
AB - Background. The aim of this study was to develop and characterize a nanoparticle-based image-contrast platform which is biocompatible, chemically stable, and accessible for radiolabeling with 201 Tl. We explored whether this nanoparticle enhanced the T1 signal which might make it an MRI contrast agent as well. Methods. The physical properties of citrate-coated Prussian blue nanoparticles (PBNPs) (iron(II);iron(III);octadecacyanide) doped with 201 Tl isotope were characterized with atomic force microscopy, dynamic light scattering, and zeta potential measurement. PBNP biodistribution was determined by using SPECT and MRI following intravenous administration into C57BL6 mice. Activity concentrations (MBq/cm 3 ) were calculated from the SPECT scans for each dedicated volume of interest (VOI) of liver, kidneys, salivary glands, heart, lungs, and brain. Results. PBNP accumulation peaked at 2 hours after injection predominantly in the kidneys and the liver followed by a gradual decrease in activity in later time points. Conclusion. We synthetized, characterized, and radiolabeled a Prussian blue-based nanoparticle platform for contrast material applications. Its in vivo radiochemical stability and biodistribution open up the way for further diagnostic applications.
UR - http://www.scopus.com/inward/record.url?scp=85046630255&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85046630255&partnerID=8YFLogxK
U2 - 10.1155/2018/2023604
DO - 10.1155/2018/2023604
M3 - Article
C2 - 29853803
AN - SCOPUS:85046630255
SN - 1555-4309
VL - 2018
JO - Contrast Media and Molecular Imaging
JF - Contrast Media and Molecular Imaging
M1 - 2023604
ER -